IDEAS home Printed from https://ideas.repec.org/a/gam/jjopen/v6y2023i2p17-235d1125752.html
   My bibliography  Save this article

The Novelty of mRNA Viral Vaccines and Potential Harms: A Scoping Review

Author

Listed:
  • Matthew T.J. Halma

    (EBMC Squared CIC, 11 Laura Place, Bath BA2 4BL, UK)

  • Jessica Rose

    (Independent Researcher)

  • Theresa Lawrie

    (EBMC Squared CIC, 11 Laura Place, Bath BA2 4BL, UK)

Abstract

Pharmacovigilance databases are showing evidence of injury in the context of the modified COVID-19 mRNA products. According to recent publications, adverse event reports linked to the mRNA COVID-19 injections largely point to the spike protein as an aetiological agent of adverse events, but we propose that the platform itself may be culpable. To assess the safety of current and future mRNA vaccines, further analysis is needed on the risks due to the platform itself, and not specifically the expressed antigen. If harm can be exclusively and conclusively attributed to the spike protein, then it is possible that future mRNA vaccines expressing other antigens will be safe. If harms are attributable to the platform itself, then regardless of the toxicity, or lack thereof, of the antigen to be expressed, the platform may be inherently unsafe, pending modification. In this work, we examine previous studies of RNA-based delivery by a lipid nanoparticle (LNP) and break down the possible aetiological elements of harm.

Suggested Citation

  • Matthew T.J. Halma & Jessica Rose & Theresa Lawrie, 2023. "The Novelty of mRNA Viral Vaccines and Potential Harms: A Scoping Review," J, MDPI, vol. 6(2), pages 1-16, April.
    • Handle: RePEc:gam:jjopen:v:6:y:2023:i:2:p:17-235:d:1125752
    as

    Download full text from publisher

    File URL: https://www.mdpi.com/2571-8800/6/2/17/pdf
    Download Restriction: no
    File URL: https://www.mdpi.com/2571-8800/6/2/17/
    Download Restriction: no
    ---><---

    References listed on IDEAS

    as
    1. Elie Dolgin, 2021. "The tangled history of mRNA vaccines," Nature, Nature, vol. 597(7876), pages 318-324, September.
    2. Ugur Sahin & Petra Oehm & Evelyna Derhovanessian & Robert A. Jabulowsky & Mathias Vormehr & Maike Gold & Daniel Maurus & Doreen Schwarck-Kokarakis & Andreas N. Kuhn & Tana Omokoko & Lena M. Kranz & Mu, 2020. "An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma," Nature, Nature, vol. 585(7823), pages 107-112, September.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Jim Middelburg & Marjolein Sluijter & Gaby Schaap & Büşra Göynük & Katy Lloyd & Vitalijs Ovcinnikovs & Gijs G. Zom & Renoud J. Marijnissen & Christianne Groeneveldt & Lisa Griffioen & Gerwin G. W. San, 2024. "T-cell stimulating vaccines empower CD3 bispecific antibody therapy in solid tumors," Nature Communications, Nature, vol. 15(1), pages 1-15, December.
    2. Wojciech Barczak & Simon M. Carr & Geng Liu & Shonagh Munro & Annalisa Nicastri & Lian Ni Lee & Claire Hutchings & Nicola Ternette & Paul Klenerman & Alexander Kanapin & Anastasia Samsonova & Nicholas, 2023. "Long non-coding RNA-derived peptides are immunogenic and drive a potent anti-tumour response," Nature Communications, Nature, vol. 14(1), pages 1-17, December.
    3. Witold Więcek, 2022. "Clinical trials for accelerating pandemic vaccines [‘A Systematic Review of Human Challenge Trials, Designs, and Safety’]," Oxford Review of Economic Policy, Oxford University Press and Oxford Review of Economic Policy Limited, vol. 38(4), pages 797-817.
    4. Boutillier, Sophie & Laperche, Blandine & Lebert, Didier & Elouaer-Mrizak, Sana, 2023. "A systemic analysis of the technological trajectory at company level based on patent data: The case of Sanofi's vaccine technology," Technovation, Elsevier, vol. 124(C).
    5. Wanbo Tai & Shengyong Feng & Benjie Chai & Shuaiyao Lu & Guangyu Zhao & Dong Chen & Wenhai Yu & Liting Ren & Huicheng Shi & Jing Lu & Zhuming Cai & Mujia Pang & Xu Tan & Penghua Wang & Jinzhong Lin & , 2023. "An mRNA-based T-cell-inducing antigen strengthens COVID-19 vaccine against SARS-CoV-2 variants," Nature Communications, Nature, vol. 14(1), pages 1-15, December.
    6. Wanzun Lin & Li Chen & Haojiong Zhang & Xianxin Qiu & Qingting Huang & Fangzhu Wan & Ziyu Le & Shikai Geng & Anlan Zhang & Sufang Qiu & Long Chen & Lin Kong & Jiade J. Lu, 2023. "Tumor-intrinsic YTHDF1 drives immune evasion and resistance to immune checkpoint inhibitors via promoting MHC-I degradation," Nature Communications, Nature, vol. 14(1), pages 1-22, December.
    7. Masahito Inagaki & Naoko Abe & Zhenmin Li & Yuko Nakashima & Susit Acharyya & Kazuya Ogawa & Daisuke Kawaguchi & Haruka Hiraoka & Ayaka Banno & Zheyu Meng & Mizuki Tada & Tatsuma Ishida & Pingxue Lyu , 2023. "Cap analogs with a hydrophobic photocleavable tag enable facile purification of fully capped mRNA with various cap structures," Nature Communications, Nature, vol. 14(1), pages 1-17, December.
    8. Martin Ho & Henry CW Price & Tim S Evans & Eoin O'Sullivan, 2023. "Order in Innovation," Papers 2302.13076, arXiv.org.
    9. Betz, Ulrich A.K. & Arora, Loukik & Assal, Reem A. & Azevedo, Hatylas & Baldwin, Jeremy & Becker, Michael S. & Bostock, Stefan & Cheng, Vinton & Egle, Tobias & Ferrari, Nicola & Schneider-Futschik, El, 2023. "Game changers in science and technology - now and beyond," Technological Forecasting and Social Change, Elsevier, vol. 193(C).
    10. Sarah Guillou & Basheer Kalash & Lionel Nesta & Michele Pezzoni & Evens Salies & Marc-Antoine Faure, 2023. "Impact de la nature du financement de la recherche sur ses résultats," SciencePo Working papers Main hal-04026916, HAL.
    11. Emily K. Ninmer & Hong Zhu & Kimberly A. Chianese-Bullock & Margaret Mehren & Naomi B. Haas & Merrick I. Ross & Lynn T. Dengel & Craig L. Slingluff, 2024. "Multipeptide vaccines for melanoma in the adjuvant setting: long-term survival outcomes and post-hoc analysis of a randomized phase II trial," Nature Communications, Nature, vol. 15(1), pages 1-12, December.
    12. Zhijian Li & Laura Amaya & Ruoxi Pi & Sean K. Wang & Alok Ranjan & Robert M. Waymouth & Catherine A. Blish & Howard Y. Chang & Paul A. Wender, 2023. "Charge-altering releasable transporters enhance mRNA delivery in vitro and exhibit in vivo tropism," Nature Communications, Nature, vol. 14(1), pages 1-15, December.

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:gam:jjopen:v:6:y:2023:i:2:p:17-235:d:1125752. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: MDPI Indexing Manager (email available below). General contact details of provider: https://www.mdpi.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.